Wesure Globaltech in the First Quarter: Ayalon Delivers Profit and CSM, Capital Moves Toward the US and Credit
Wesure Globaltech opened 2026 with higher shareholder profit, stronger Ayalon core earnings, and a better CSM rebuild. But the same quarter also shifts the debate to capital allocation: dividends, credit, provident funds, the US platform, and insurance agencies are starting to compete for the same financial flexibility.
Wesure Globaltech reported a first quarter that strengthens the insurance core, but also shows how much the next stage depends on disciplined capital allocation at the parent level. Ayalon remains the main earnings source: its general-insurance core profit rose despite lower premiums, CSM in life and health was replenished at a rate that covered the quarterly release, and investment contracts jumped in a way that deepens the savings platform. That partly closes the question left after 2025, whether the central insurance company can truly carry the group while the new arms are still being built. Still, the quarter does not make the story clean: Wesure Insurance itself delivered weaker core profit and needed a capital injection to move above its solvency target, the US companies are still weighing on the “other” line, and the parent is beginning to pull capital in several new directions. The filing therefore shifts the debate from first-quarter profit to the quality of 2026 capital use. The current read is cautiously positive: the core is improving, but shareholders still need to see that the cash and capital generated inside the group are not spread too quickly before the new arms prove earnings and cash flow.
Ayalon Holds the Quarter, but Not Every Part of the Group Has the Same Quality
The group is now less a digital-insurance company and more an insurance and financial holding company. As of the reporting date, the company held 61.58% of the central insurance subsidiary, or 57.96% fully diluted. Around the publication date, that stake declined to 61.25%, or 57.82% fully diluted, following the exercise of options. Alongside the insurance subsidiary, the group also operates Wesure Insurance, US activities, an early-stage credit and surety business, and a new license to manage provident funds.
In the previous annual analysis, the open question was whether the central insurer could continue to provide profit and capital while the US, credit, and provident-fund arms moved from setup to proof. In the first quarter, profit attributable to shareholders rose to NIS 44.0 million from NIS 35.1 million in the comparable quarter, and pre-tax profit was NIS 106.1 million versus NIS 80.3 million. Those numbers are good, but the breakdown matters more than the headline.
Group core profit was NIS 109.1 million, compared with NIS 85.7 million. Within that, the central insurer’s general-insurance business contributed NIS 82.2 million of core profit, versus NIS 60.2 million, even though the excess financial margin in the segment was more negative: a loss of NIS 24.8 million compared with a loss of NIS 6.2 million. In other words, the improvement came from the insurance business itself, not only from a supportive capital market. Even the decline in gross premiums in general insurance, from NIS 940.7 million to NIS 837.3 million, did not prevent core profit from improving.
At Wesure Insurance, the picture is weaker. Comprehensive pre-tax profit rose to NIS 7.1 million from NIS 6.0 million, but core profit fell to NIS 4.8 million from NIS 7.4 million. Motor property improved thanks to premium growth and lower claims frequency, but motor liability moved to a NIS 1.9 million core loss from a NIS 5.9 million profit. Health also did not repeat the comparable quarter, with core profit falling to NIS 19.7 million from NIS 29.9 million. Capital and other still includes the US companies, and the “other” component moved to a NIS 5.1 million loss from a NIS 0.8 million profit, mainly because of losses in the US companies.
CSM and Investment Contracts Add Depth That Net Profit Does Not Show
The figure that improves the quality of the quarter is CSM, the contractual service margin that represents future profit not yet recognized under IFRS 17 in life and health insurance contracts. Net CSM stood at NIS 1.079 billion at quarter-end, compared with NIS 1.058 billion at the end of 2025 and NIS 1.036 billion at the end of the comparable quarter. The movement inside the quarter matters more than the balance: NIS 48 million of new CSM was created, while the combined release from runoff and growth products was NIS 47 million.
The ratio of new CSM to release reached 102% across the portfolio, versus 51% in the comparable quarter. In growth products, the ratio was 187%, compared with 114% in the comparable quarter. This means the quarter did not only release profits accumulated in the past. It renewed them at a higher pace, especially in the products expected to carry the future activity.
This is joined by a sharp change in investment contracts. Proceeds from investment contracts totaled NIS 1.326 billion in the quarter, compared with NIS 129.6 million in the comparable quarter, and are already close to the entire 2025 amount of NIS 1.660 billion. Investment-contract assets reached NIS 3.939 billion, up 47% from the end of 2025 and 173% from the end of 2024. Total group assets under management stood at NIS 16.684 billion, up 9% from the end of 2025 and 25% from the end of 2024.
Still, this is not cash that drops directly into the parent’s profit line. The filing states that around NIS 6 million of variable management fees were collected during the quarter, compared with around NIS 1 million in the comparable quarter, but recognition is made through CSM over time. That is the distinction: the figure strengthens future earnings depth, but it requires accounting and operating patience before it becomes recognized profit and cash that can move up the group.
Capital Is Already Being Pulled Toward the US, Credit, and Dividends
The parent’s liquidity position looks comfortable. In the solo statements, cash and cash equivalents were NIS 372.3 million, against current liabilities of NIS 30.7 million. Solo equity stood at NIS 1.285 billion, and the equity-to-balance-sheet ratio was about 83%, far from the bond covenants. The bond is unsecured, carries a fixed shekel interest rate of 4.25%, and principal repayment begins only in March 2029.
But this cash is no longer only a cushion. In April 2026, the company approved a private placement to seven classified investors for NIS 116.5 million. In May, the company approved an interim dividend of about NIS 20 million, while the insurance subsidiary approved a NIS 30 million dividend, of which the company’s share is about NIS 18.4 million. In parallel, in February the company approved an intercompany credit facility of up to NIS 50 million for Globaltech Finance, and in March an expanded credit and guarantee license was received.
| Capital use or source | Amount or status | Economic meaning |
|---|---|---|
| April 2026 private placement | NIS 116.5 million | Strengthens the parent’s cash position after quarter-end |
| Parent interim dividend | About NIS 20 million | Cash exits to shareholders already in the second quarter |
| Dividend from the insurance subsidiary | NIS 30 million, company share about NIS 18.4 million | Cash moves up from the subsidiary, but depends on continued surplus capital and underwriting quality |
| Globaltech Finance facility | Up to NIS 50 million | Credit and surety activity begins to consume capital |
| UBIC memorandum | USD 300,000 capital note, with potential additional capital of USD 6 million to USD 10 million | The US remains a growth option that needs capital before earnings proof |
| Potential Tier 1 issuance at the insurance subsidiary | Up to NIS 350 million | Possible regulatory capital reinforcement, alongside a potential early redemption of Tier 2 debt |
The US front shows the two-sided nature of the story. In the previous US analysis, the focus was that moving from a memorandum of understanding to acquiring a US insurer requires capital, approvals, and a binding agreement. The current filing adds two details: the company has already invested USD 300,000 in a convertible Tier 2 capital note of UBIC, and if the transaction is completed it may need to inject another USD 6 million to USD 10 million, while the US companies are still producing a loss in the “other” line. The US is therefore still a funded option, not an earnings source funding the group.
Solvency also sharpens the gap between the core and the rest of the group. At the central insurance company, the solvency ratio stood at the end of 2025 at 130% without transitional measures and 136% with transitional measures, and after option exercises rose to 131% and 137%. At Wesure Insurance, the ratio was only 98% before a NIS 16 million Tier 1 capital injection from the central subsidiary, and only then rose to 106%. This is not an existential problem, but it reminds investors that not every part of the group releases capital with the same ease.
The short position is therefore not a side detail. Local market data show that the short position in the share reached 8.0% of float on May 20, 2026, with an SIR of 12.81, compared with a sector average of 1.79% and 3.19, respectively. This is not recommendation language, but it explains the market’s sensitivity: investors may reward the core improvement, yet any US delay, solvency pressure, or excessively broad capital spread can pull the discussion back to execution risk.
Conclusion
The first quarter of 2026 improves the read on the core: the central insurance company delivered strong core profit in general insurance, better CSM replenishment, and unusual growth in investment contracts. These are not just profit numbers. They are signs that the parent’s central asset continues to deepen. If this continues, the company can present 2026 as a proof year in which the core not only distributes profits but also funds a broader financial expansion.
The constraint is that capital is already being asked to work in too many places before all of them have proven themselves. The US is still loss-making, UBIC may require additional capital, Globaltech Finance is only beginning to operate, provident funds have not yet shown a commercial contribution, Wesure Insurance needs to preserve its capital buffer, and the agency move has not yet advanced from a proposal to binding negotiations. The checkpoints for the next two to four quarters are clear: whether core profit remains strong if the financial market becomes less supportive, whether CSM and investment contracts continue to replenish, whether the parent allocates capital without weakening solo flexibility, and whether one of the new arms begins to show recurring profit rather than only a capital requirement.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.